Enobosarm, a selective androgen receptor modulator (SARM), is being evaluated as a targeted treatment for advanced breast cancer.
The Company has an ongoing open-label, Phase 2 clinical trial of enobosarm to assess clinical benefit in women with metastatic or locally advanced, estrogen receptor positive (ER+) and androgen receptor positive (AR+) breast cancer. The study is fully enrolled with at least 44 evaluable patients enrolled in two dose cohorts (9 mg and 18 mg). The pre-specified threshold for success was attained in the 9 mg cohort, with nine patients achieving a clinical benefit response (CBR) at 24 weeks among the first 22 evaluable patients in that cohort.
More information about our clinical trials may be found on clinicaltrials.gov.
More information on Breast Cancer may be found here.
More information concerning expanded access for enobosarm may be found here.